Core Scientific's largest shareholder to vote against sale to CoreWeave

Two Seas Capital, the largest shareholder of Core Scientific with a 6.3% stake, has publicly announced its opposition to CoreWeave's proposed $9 billion all-stock acquisition of the crypto miner. The investment firm contends the deal "materially undervalues" Core Scientific and exposes shareholders to "substantial economic risk," potentially complicating the completion of the acquisition.

Analysis

The proposed $9 billion all-stock acquisition of Core Scientific (CORZ) by CoreWeave (CRWV) faces a significant obstacle following public opposition from Two Seas Capital, Core Scientific's largest shareholder with a 6.3% stake. The investment firm's assertion that the deal "materially undervalues" CORZ and introduces "substantial economic risk" transforms the M&A process into a potential governance battle, casting uncertainty on the deal's completion. The market reaction reflects this new risk, with CORZ shares trading marginally down, indicating that the acquisition premium is now in jeopardy. The negative sentiment score for CORZ (-0.7) quantifies this concern. This shareholder activism introduces a critical variable that could force CoreWeave to revise its offer, prompt a proxy fight, or lead to the deal's collapse.

Key Decisions for Investors

• Investors in Core Scientific should recognize the heightened risk of deal failure; the stock's value is now primarily driven by the probability of the acquisition closing rather than standalone fundamentals.
• Merger arbitrage positions face increased uncertainty, and traders should monitor for a revised, higher offer from CoreWeave or the emergence of a competing bidder as potential outcomes of this shareholder dissent.
• For CoreWeave investors, the key consideration is whether management will engage in a costly bidding war, potentially increasing share dilution, or walk away from the deal, which would have different strategic implications for its growth.